The Food and Drug Administration has approved Zoryve (roflumilast) topical foam, 0.3% for plaque psoriasis of the scalp and ...

New psoriasis drug Zoryve approved. How to use & why Black American participation in clinical trials is vital for health ...

Dr. Sharda Ayurveda has achieved a remarkable approach towards Psoriasis management with Ayurveda. According to Dr. Mukesh Sharda, it is a serious disease that can impact any generation. A sedentary ...

Symptoms, lesion locations, and morphology are among the features clinicians may use to distinguish hand eczema from hand psoriasis in patients.

The U.S. Food and Drug Administration has approved Arcutis Biotherapeutics' Zoryve (roflumilast) topical foam 0.3% for the ...

The 0.3% foam formulation of roflumilast was previously approved for the treatment of seborrheic dermatitis in adults and ...

The FDA approved a supplemental new drug application for roflumilast topical foam 0.3% for the treatment of plaque psoriasis ...

In addition, scalp psoriasis occurs in more than half of ... cream 0.05% is under review for the treatment of atopic dermatitis in children ages 2 to 5 by the FDA, with a PDUFA target action ...

Arcutis Biotherapeutics Inc (ARQT) reports a remarkable 196% year-over-year revenue increase, driven by strong demand for ZORYVE and strategic advancements in product offerings.

According to the National Psoriasis Foundation, every year, roughly 20,000 children under age 10 are diagnosed with psoriasis. When the scalp is affected—something nearly half of patients ...

Scalp psoriasis shows up as itchy ... When she’s not writing, she enjoys spending time with her husband and four children, traveling, and cheering on the UCF Knights.